Biotech
🔥 Lilly Just Paid Up to $2.88 Billion for a Startup With Zero Approved Drugs
Eli Lilly is paying up to $2.88 billion for Merida Biosciences, a 16-month-old startup whose lead autoimmune drug is still in Phase 1.
What's new in
Pharma
Biotech
🔥 A Once-Daily Pill Nearly Doubled Pancreatic Cancer Survival. Wall Street Shrugged.
Revolution Medicines' RASONQUE is the first broad RAS-targeted pill for metastatic pancreatic cancer, nearly doubling median survival to 13.2 months. The catch: $39,800 a month.
Biotech
🔥 A Pill Just Doubled Survival in Pancreatic Cancer. The FDA Cleared It in About a Month — at $477,000 a Year.
The FDA cleared Revolution Medicines' daraxonrasib, the first broad RAS-targeted pill for metastatic pancreatic cancer, doubling median survival to 13.2 months at a $477,000-a-year list price.
Biotech
🔥 Ultragenyx's First Gene Therapy Costs $2.7 Million. It Buys GSDIa Patients Freedom From the Cornstarch Clock.
The FDA cleared GENGLYCOS, Ultragenyx's first gene therapy: a one-time $2.7 million infusion targeting the root cause of glycogen storage disease type Ia.
More stories
Biotech
🔥 AusperBio Raised $120 Million on a Hepatitis B Drug That Cleared the Virus in 68% of a Small Trial
AusperBio raised $120M to push AHB-137, an antisense drug that cleared hepatitis B in 68% of a small trial, toward the first functional cure for a disease 240 million people live with.
Biotech
🔥 Moderna and Merck's Cancer Vaccine Cleared Phase 3. The Stock Doubled Before Anyone Saw the Numbers.
Moderna and Merck's personalized mRNA cancer vaccine cleared Phase 3 in 1,137 melanoma patients — and Moderna's stock more than doubled before the full numbers were even released.
Biotech
🔥 Takeda Cracked Orexin. Its First-in-Class Narcolepsy Pill Could Do $2 Billion.
Takeda's Orzeyful is the first-in-class orexin agonist cleared to treat narcolepsy type 1 at its root cause — and Jefferies pegs peak sales near $2 billion.
Biotech
🔥 Bristol Myers Just Launched a Whole New Class of Myeloma Drug — and Priced It at $29,500 a Cycle
Bristol Myers Squibb's Zenbexus is the first CELMoD approved for multiple myeloma — cleared on a doubled deep-remission rate (41% vs 21%) and priced at $29,500 a cycle.
Biotech
🔥 Jazz Just Paid $820 Million for an Epilepsy Drug Still Stuck in Phase 1 — and It's Meant for 2,500 People
Jazz Pharmaceuticals is paying $820M upfront — up to $1.32B — for Actio Biosciences and its Phase 1 KCNT1 epilepsy drug, aimed at just ~2,500 U.S. patients.
Biotech
🔥 Moderna's mRNA Flu Shot Beat the Standard Jab by 27% — and the FDA Nearly Never Reviewed It
The FDA just approved mFlusiva, the first mRNA flu vaccine ever — 26.6% more effective than the standard shot in adults 50+, six months after the agency refused to review it.
AI
🔥 An AI Drug Company Just Committed $2.2 Billion — Without Discovering a Single Molecule
Pathos AI committed up to $2.2 billion to license cancer drugs from Alphamab and AstraZeneca without inventing a single molecule. Inside the bet that AI's real job is picking patients, not chemistry.
Pharma
🔥 Lilly and Resilience Just Put $750 Million Into Ohio to Make More Weight-Loss Pens
Lilly and its manufacturing partner Resilience are putting $750 million into an Ohio campus to make more of the injector pens behind the diabetes and obesity boom -- 400 new jobs, full operations by early 2027.